XB130 expression in human osteosarcoma: a clinical and experimental study

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Identifying prognostic factors for osteosarcoma (OS) is crucial for tailoring aggressive treatment strategies.
• XB130, an adaptor protein, is a known prognostic factor in other cancers, but its role in OS is unexplored.

Purpose of the Study:

• To investigate the association between XB130 expression and clinicopathologic features, prognosis, and metastatic potential in osteosarcoma.
• To explore the functional role of XB130 in OS cell invasion and metastasis in vitro and in vivo.

Main Methods:

• Retrospective immunohistochemical analysis of XB130 expression in 60 osteosarcoma and noncancerous bone tissue pairs.
• Correlation of XB130 expression with clinicopathological parameters and patient survival.
• Assessment of XB130 silencing effects on OS cell invasion (in vitro) and lung metastasis (in vivo) using RNA interference.

Main Results:

• XB130 expression was significantly higher in OS tissues compared to noncancerous tissues (P=0.001).
• High XB130 expression correlated with advanced clinical stage (P=0.002) and distant metastasis (P=0.001).
• Patients with high XB130 expression exhibited significantly shorter overall and disease-free survival (P<0.001).
• XB130 depletion inhibited OS cell invasion and lung metastasis.
• High XB130 expression and distant metastasis were identified as independent poor prognostic factors.

Conclusions:

• XB130 overexpression is associated with poor prognosis and increased metastatic potential in osteosarcoma.
• XB130 may serve as a prognostic biomarker for optimizing clinical treatment strategies in OS patients.
• XB130 represents a potential molecular target for novel osteosarcoma therapies.